Ketorolac Ophthalmic Solution — Competitive Intelligence Brief

Ketorolac Ophthalmic Solution (Ketorolac Ophthalmic Solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Ophthalmology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Ophthalmology Small molecule

Target snapshot

Ketorolac Ophthalmic Solution (Ketorolac Ophthalmic Solution) — Bausch & Lomb Incorporated. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation in the eye.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketorolac Ophthalmic Solution TARGET	Ketorolac Ophthalmic Solution	Bausch & Lomb Incorporated	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
ketorolac 0.5%	ketorolac 0.5%	Queen's University	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
standard pain relievers	standard pain relievers	GCS Ramsay Santé pour l'Enseignement et la Recherche	marketed	Nonsteroidal anti-inflammatory drug (NSAID) or analgesic	COX-1 and/or COX-2 enzymes (for NSAIDs); central pain pathways (for acetaminophen)
optimized ibuprofen	optimized ibuprofen	OSF Healthcare System	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Standard Dose Ibuprofen	Standard Dose Ibuprofen	Ottawa Hospital Research Institute	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1, COX-2
Ketorolac Tromethamine Injection	Ketorolac Tromethamine Injection	UConn Health	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Experimental: Aspirin monotherapy	Experimental: Aspirin monotherapy	Chinese Academy of Medical Sciences, Fuwai Hospital	marketed	Nonsteroidal anti-inflammatory drug (NSAID) / Antiplatelet agent	COX-1, COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class